185 related articles for article (PubMed ID: 37199872)
1. Depiction of neuroendocrine features associated with immunotherapy response using a novel one-class predictor in lung adenocarcinoma.
Liu H; Han Y; Liu Z; Gao L; Yi T; Yu Y; Wang Y; Qu P; Xiang L; Li Y
Discov Oncol; 2023 May; 14(1):71. PubMed ID: 37199872
[TBL] [Abstract][Full Text] [Related]
2. [Clinical Characteristics, Treatment and Prognosis of 47 Non-small Cell Lung Cancer with Neuroendocrine Differentiation Patients].
Li X; Xu H; Kang X; Zhao J; Lin Y; Wang S; Liu X
Zhongguo Fei Ai Za Zhi; 2019 Aug; 22(8):507-511. PubMed ID: 31451141
[TBL] [Abstract][Full Text] [Related]
3. Machine learning identifies characteristics molecules of cancer associated fibroblasts significantly correlated with the prognosis, immunotherapy response and immune microenvironment in lung adenocarcinoma.
Wang Q; Zhang X; Du K; Wu X; Zhou Y; Chen D; Zeng L
Front Oncol; 2022; 12():1059253. PubMed ID: 36439484
[TBL] [Abstract][Full Text] [Related]
4. Erk/MAP kinase signaling pathway and neuroendocrine differentiation of non-small-cell lung cancer.
Chen Y; Nowak I; Huang J; Keng PC; Sun H; Xu H; Wei G; Lee SO
J Thorac Oncol; 2014 Jan; 9(1):50-8. PubMed ID: 24346093
[TBL] [Abstract][Full Text] [Related]
5. Wnt signaling pathway-derived score for predicting therapeutic resistance and tumor microenvironment in lung adenocarcinoma.
Zhou HM; Zhao LM
Front Pharmacol; 2022; 13():1091018. PubMed ID: 36703749
[No Abstract] [Full Text] [Related]
6. PRMT5 promotes chemotherapy-induced neuroendocrine differentiation in NSCLC.
Shen Q; Liu Y; Deng X; Hu CD
Thorac Cancer; 2023 Jun; 14(18):1764-1773. PubMed ID: 37140020
[TBL] [Abstract][Full Text] [Related]
7. Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures.
Wu Q; Wang L; Wei H; Li B; Yang J; Wang Z; Xu J; Zhou YL; Zhang B
Int Immunopharmacol; 2020 Jun; 83():106477. PubMed ID: 32278127
[TBL] [Abstract][Full Text] [Related]
8. High Expression of
Chen Y; Zhou M; Gu X; Wang L; Wang C
Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850
[TBL] [Abstract][Full Text] [Related]
9. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
10. Low expression of INMT is associated with poor prognosis but favorable immunotherapy response in lung adenocarcinoma.
Zhou X; Zou B; Wang J; Wu L; Tan Q; Ji C
Front Genet; 2022; 13():946848. PubMed ID: 36437916
[No Abstract] [Full Text] [Related]
11. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
[TBL] [Abstract][Full Text] [Related]
12. Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy.
Li C; Pan J; Luo J; Chen X
BMC Pulm Med; 2021 Nov; 21(1):389. PubMed ID: 34844602
[TBL] [Abstract][Full Text] [Related]
13. Improving differential diagnosis of pulmonary large cell neuroendocrine carcinoma and small cell lung cancer via a transcriptomic, biological pathway-based machine learning model.
Guo J; Hou L; Zhang W; Dong Z; Zhang L; Wu C
Transl Oncol; 2021 Dec; 14(12):101222. PubMed ID: 34530194
[TBL] [Abstract][Full Text] [Related]
14. Transcriptomic FHIT
Brisebarre A; Ancel J; Ponchel T; Loeffler E; Germain A; Dalstein V; Dormoy V; Durlach A; Delepine G; Deslée G; Polette M; Nawrocki-Raby B
Front Immunol; 2022; 13():1058531. PubMed ID: 36544755
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis.
Zhu M; Zeng Q; Fan T; Lei Y; Wang F; Zheng S; Wang X; Zeng H; Tan F; Sun N; Xue Q; He J
Front Immunol; 2022; 13():783495. PubMed ID: 35222371
[TBL] [Abstract][Full Text] [Related]
16. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Wang J; Zhan X
Front Immunol; 2021; 12():752643. PubMed ID: 34887858
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analyses of one-carbon metabolism related genes and their association with prognosis, tumor microenvironment, chemotherapy resistance and immunotherapy in lung adenocarcinoma.
Zhou N; Tang Q; Yu H; Li T; Ren F; Zu L; Chen G; Chen J; Xu S
Front Mol Biosci; 2022; 9():1034208. PubMed ID: 36438661
[No Abstract] [Full Text] [Related]
18. Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer.
Huang L; Feng Y; Xie T; Zhu H; Tang L; Shi Y
BMC Cancer; 2023 Apr; 23(1):312. PubMed ID: 37020179
[TBL] [Abstract][Full Text] [Related]
19. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles.
Jones MH; Virtanen C; Honjoh D; Miyoshi T; Satoh Y; Okumura S; Nakagawa K; Nomura H; Ishikawa Y
Lancet; 2004 Mar; 363(9411):775-81. PubMed ID: 15016488
[TBL] [Abstract][Full Text] [Related]
20. Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma.
Jia H; Tang WJ; Sun L; Wan C; Zhou Y; Shen WZ
Front Genet; 2022; 13():1017866. PubMed ID: 36699466
[No Abstract] [Full Text] [Related]
[Next] [New Search]
